1 Adverse events were recorded at baseline, 3 hours, and 24 hours postt
2 Adverse events were recorded from (64)Cu-DOTATATE injection through 4
3 Adverse events were recorded in 131 (57%) of 231 patients in the exen
4 Adverse events were recorded in 82 (54%) patients who received placeb
5 Adverse events were recorded throughout the study.
6 125
adverse events were recorded, of which 117 were treatment emergent an
7 A total of 2,303
adverse events were recorded for 502 patients (63%).
8 No grade 4
adverse events were recorded and no treatment-related deaths were rep
9 course, visual outcomes, ocular complications, and
adverse events were recorded.
10 visit, disease activity score, weight, therapy, and
adverse events were recorded; drug and total anti-drug antibody conce
11 y medication), 63 suspected grade 3 or 4 associated
adverse events were recorded among 57 (3%) children; 31 (2%) in the c
12 Survival outcomes and clinical or biochemical
adverse events were recorded.
13 Grade 3-4 treatment-emergent
adverse events were recorded in 21 (37%) of 57 patients, most commonl
14 No
adverse events were recorded.
15 Nonserious
adverse events were recorded in 934 participants, most of whom (67.5%
16 No significant changes in seizure frequency or
adverse events were recorded.
17 Predefined sedation-related
adverse events were recorded daily.
18 Treatment-related
adverse events were recorded in 20 (13%) patients receiving RS8 and i
19 ere well tolerated, and no severe treatment-related
adverse events were recorded throughout the study.
20 HC-102 was well tolerated and no study drug-related
adverse events were recorded.
21 Fourteen serious
adverse events were recorded and resolved.
22 A total of 312 serious
adverse events were recorded in 110 patients.
23 Serious
adverse events were recorded in 117 (48%) of 246 patients.
24 Serious
adverse events were recorded in 2 of 15 patients (anaemia in 1 patien
25 26 serious
adverse events were recorded in 21 (10%) infants across the study per
26 Serious
adverse events were recorded in 238 (60%) of the total population, an
27 Serious
adverse events were recorded in 30 and 40 patients, respectively.
28 Serious
adverse events were recorded in three (3%) patients who received meth
29 Serious
adverse events were recorded throughout the study in all vaccinated c
30 24 serious
adverse events were recorded, consisting of 23 hospital admissions an
31 bly or definitely related adverse events or serious
adverse events were recorded.
32 No serious
adverse events were recorded.
33 No severe
adverse events were recorded.
34 Mild, transient
adverse events were recorded in 32% of patients treated with cooling
35 Unsolicited
adverse events were recorded for 28 days.
36 Solicited and unsolicited
adverse events were recorded, and immune responses were measured.
37 Major
bleeding events were recorded after a median of 6.5 years follow-up.
38 ding 44,989 participants, in whom 2496 major
cardiovascular events were recorded during a mean 3.8 years of follow-up (ra
39 and overall major adverse cardiovascular or
cerebrovascular events were recorded.
40 Claustrophobic events were recorded by the staff.
41 cal outcomes of mortality, CVD events, DM, and bone
disease events were recorded throughout the study period (baseline to
42 t, mode of delivery and feeding, immunizations, and
medical events) were recorded.
43 Multiple events were recorded in 22.7% admissions; 15% of these experi
44 1626 kidney events, 795 eye events, and 7598
nerve events were recorded during the follow-up period (median 5.0
45 ome potentially related to magnesium sulphate treatment,
no events were recorded from the 2 trials providing data.
46 ] age, 26 [6] years) in the study, 1018 adverse
obstetrical events were recorded in 953 pregnant women (4.8%).
47 baseline, 56 years [SD, 8 years]), 4607 CHD and 3253
stroke events were recorded (median follow-up, 8.1 years).
48 baseline, 63 years [SD, 9 years]), 5078 CHD and 3932
stroke events were recorded (median follow-up, 9.5 years).
49 Burst
suppression events were recorded before and after creation of the focus u
50 A total of 80
VF events were recorded in the implantable cardioverter-defibril